Genomics of Chronic Renal Allograft Rejection
慢性同种异体移植肾排斥的基因组学
基本信息
- 批准号:8100582
- 负责人:
- 金额:$ 31.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-08-05 至 2012-07-31
- 项目状态:已结题
- 来源:
- 关键词:AlloantigenAllograftingAnimalsAntibodiesAntibody FormationArteriesArtsBasement membraneBioinformaticsBiological AssayBiopsyBlood capillariesCD4 Positive T LymphocytesCellsChronicChronic Allograft ArteriopathyChronic rejection of renal transplantCollaborationsDataDevelopmentEpitopesEventFrequenciesGene ActivationGene ExpressionGene Expression ProfileGenesGeneticGenetic PolymorphismGenomicsGenotypeGraft SurvivalHumanImmuneImmune responseImmunoglobulin Class SwitchingImmunoglobulin GImmunologic FactorsImmunologicsImmunosuppressive AgentsIndividualIndolentInflammatoryInheritedInjuryIsoantibodiesKidney TransplantationMHC antigenMediatingMicroarray AnalysisMolecular ProfilingMononuclearMorphologyNaturePathologicPathologic ProcessesPathologyPathway interactionsPatientsPatternPeptide/MHC ComplexPeptidesPeripheral Blood LymphocytePredispositionProcessProspective StudiesProtocols documentationResearch PersonnelResourcesRiskRoleStratificationSystemT-LymphocyteTechniquesTimeTransplant RecipientsTransplantationTransplantation ImmunologyVariantallograft rejectionbasecapillarycomplement C4denzyme linked immunospot assayglomerular basement membranegraft functioninsightisoimmunitykidney allograftnovelpatient populationpredictive modelingpreventprogramsprospectiveresearch studyresponsetherapeutic target
项目摘要
DESCRIPTION (provided by applicant): Chronic allograft nephropathy (CAN) remains the most common cause of graft loss. However, the term CAN does not delineate the specific underlying pathologic process but rather refers to the chronic injury resulting from multiple potential factors. More recently it has been suggested that the pathologic findings of chronic allograft glomerulopathy, chronic allograft arteriopathy, and lamination of the peritubular capillary basement membrane, arise due to a chronic immunologic process and therefore should be referred to as true chronic rejection. There are extensive animal and initial human studies suggesting that indirect recognition of alloantigen and/or alloantibody responses mediate this process. There are however no studies which prospectively examine whether the development of the chronic allograft rejection correlates with immune
reactivity. The principal hypothesis of this project is that chronic rejection is mediated by an ongoing indolent specific immune reactivity driven by allopeptide specific CD4+ T cell clones (indirect pathway), which gives rise to cell-mediated and antibody responses directed against the mismatched MHC antigens of the graft; The specific aims of this proposal are to: 1. Determine the role of cell mediated and antibody-mediated immune responses in chronic rejection: We will determine if the pathologic finding of chronic rejection is associated with indirect alloreactivity and/or the development of de novo DSA; 2. Determine the gene expression profile associated with the development of chronic rejection: We will study intragraft expression patterns of key genes involved in the alloimmune, innate and antibody mediated responses at the time of transplantation and prospectively post-transplant to define the level of association between intragraft events and immune responses. We will determine if specific gene expression profiles predict the development of chronic rejection using microarray analysis; 3. Determine whether polymorphic variants of specific immunological genes confer susceptibility to chronic rejection: We plan to prospectively define transplant recipients genotypes for specific immunological genes in order to identify those genotypes associated with chronic rejection and the development of an immune response directed toward the graft. The results of these studies will lend greater insight to the underlying mechanisms leading to chronic rejection and help differentiate one cause of CAN.
描述(由申请人提供):慢性同种异体移植肾病(CAN)仍然是移植物丢失的最常见原因。然而,CAN这个术语并没有描述具体的潜在病理过程,而是指由多种潜在因素引起的慢性损伤。最近有人提出,慢性同种异体移植肾小球病、慢性同种异体移植物动脉病和肾小管周围毛细血管基底膜分层的病理结果是由于慢性免疫过程而产生的,因此应被称为真正的慢性排斥反应。大量的动物和初步人类研究表明,同种抗原和/或同种抗体反应的间接识别介导了这一过程。然而,目前还没有研究前瞻性地检验慢性同种异体移植排斥的发生是否与免疫相关。
反应性。该项目的主要假设是,慢性排斥反应是由同种肽特异性 CD4+ T 细胞克隆(间接途径)驱动的持续惰性特异性免疫反应介导的,该反应引起针对不匹配的 MHC 抗原的细胞介导和抗体反应。接枝;该提案的具体目标是: 1. 确定细胞介导和抗体介导的免疫反应在慢性排斥反应中的作用:我们将确定慢性排斥反应的病理发现是否与间接同种异体反应性和/或从头发生相关DSA; 2. 确定与慢性排斥反应发生相关的基因表达谱:我们将研究移植时和移植后前瞻性的同种免疫、先天和抗体介导的反应中涉及的关键基因的移植内表达模式,以确定关联水平移植物内事件和免疫反应之间的关系。我们将使用微阵列分析确定特定的基因表达谱是否可以预测慢性排斥反应的发展; 3.确定特定免疫基因的多态性变异是否会导致对慢性排斥反应的易感性:我们计划前瞻性地定义移植受者的特定免疫基因基因型,以识别与慢性排斥和针对移植物的免疫反应的发展相关的基因型。这些研究的结果将有助于我们更深入地了解导致慢性排斥反应的潜在机制,并有助于区分 CAN 的一种原因。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Barbara T. Murphy其他文献
Barbara T. Murphy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Barbara T. Murphy', 18)}}的其他基金
An intronic locus determines SHROOM3-expression and potentiates renal allograft fibrosis
内含子位点决定 SHROOM3 表达并增强肾同种异体移植纤维化
- 批准号:
8964994 - 财政年份:2015
- 资助金额:
$ 31.8万 - 项目类别:
An intronic locus determines SHROOM3-expression and potentiates renal allograft fibrosis
内含子位点决定 SHROOM3 表达并增强肾同种异体移植纤维化
- 批准号:
9749960 - 财政年份:2015
- 资助金额:
$ 31.8万 - 项目类别:
Genomics of Chronic Renal Allograft Rejection
慢性同种异体移植肾排斥的基因组学
- 批准号:
8529741 - 财政年份:2012
- 资助金额:
$ 31.8万 - 项目类别:
Mount Sinai Institutes for Clinical and Translational Sciences
西奈山临床和转化科学研究所
- 批准号:
8060556 - 财政年份:2009
- 资助金额:
$ 31.8万 - 项目类别:
Mount Sinai Institutes for Clinical and Translational Sciences
西奈山临床和转化科学研究所
- 批准号:
8060566 - 财政年份:2009
- 资助金额:
$ 31.8万 - 项目类别:
GENOMICS OF CHRONIC RENAL ALLOGRAFT REJECTION
慢性同种异体肾移植排斥的基因组学
- 批准号:
7953702 - 财政年份:2009
- 资助金额:
$ 31.8万 - 项目类别:
Mount Sinai Institutes for Clinical and Translational Sciences
西奈山临床和转化科学研究所
- 批准号:
8060582 - 财政年份:2009
- 资助金额:
$ 31.8万 - 项目类别:
Genomics of Chronic Renal Allograft Rejection
慢性同种异体移植肾排斥的基因组学
- 批准号:
7924421 - 财政年份:2009
- 资助金额:
$ 31.8万 - 项目类别:
Genomics of Chronic Renal Allograft Rejection
慢性同种异体移植肾排斥的基因组学
- 批准号:
7273709 - 财政年份:2006
- 资助金额:
$ 31.8万 - 项目类别:
Genomics of Chronic Renal Allograft Rejection
慢性同种异体移植肾排斥的基因组学
- 批准号:
7664558 - 财政年份:2006
- 资助金额:
$ 31.8万 - 项目类别:
相似国自然基金
过表达MicroRNA-199a-3p的BMSCs来源的外泌体抑制小鼠DC功能诱导同种异体心脏移植免疫耐受的机制研究
- 批准号:82160081
- 批准年份:2021
- 资助金额:34 万元
- 项目类别:地区科学基金项目
胸腺上皮细胞在小鼠后肢同种异体复合组织移植中的免疫调节作用及相关机制研究
- 批准号:82102354
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
具有靶向识别和序贯治疗功能的纳米微球对血管化同种异体复合组织移植术后免疫抑制的研究
- 批准号:
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
基于T细胞亚群分化与TLR2/TRAF6信号通路探讨ESAT-6抑制同种异体移植排斥的分子免疫机制
- 批准号:82071800
- 批准年份:2020
- 资助金额:55 万元
- 项目类别:面上项目
TIGIT活化CD155信号促进调节性APC产生诱导异体复合组织移植免疫耐受的机制及应用研究
- 批准号:81901980
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Mechanisms of alloantibody production following renal transplantation
肾移植后同种抗体产生的机制
- 批准号:
10357956 - 财政年份:2021
- 资助金额:
$ 31.8万 - 项目类别:
Mechanisms of alloantibody production following renal transplantation
肾移植后同种抗体产生的机制
- 批准号:
10228265 - 财政年份:2021
- 资助金额:
$ 31.8万 - 项目类别:
Mechanisms of alloantibody production following renal transplantation
肾移植后同种抗体产生的机制
- 批准号:
10551197 - 财政年份:2021
- 资助金额:
$ 31.8万 - 项目类别:
A Novel and Clinically Feasible Co-therapy of Deceased Donor Bone Marrow Combined With Donor-Matched Mesenchymal Stem Cells to Establish Immune Tolerance
一种新颖且临床可行的联合疗法,将已故供体骨髓与供体匹配的间充质干细胞相结合,以建立免疫耐受
- 批准号:
10081139 - 财政年份:2020
- 资助金额:
$ 31.8万 - 项目类别:
A Novel and Clinically Feasible Co-therapy of Deceased Donor Bone Marrow Combined With Donor-Matched Mesenchymal Stem Cells to Establish Immune Tolerance
一种新颖且临床可行的联合疗法,将已故供体骨髓与供体匹配的间充质干细胞相结合,以建立免疫耐受
- 批准号:
10212956 - 财政年份:2020
- 资助金额:
$ 31.8万 - 项目类别: